



Date:13/08/2014

To

BSE Limited  
Listing Department  
P.J.Towers,Dalal Street,  
Mumbai – 400001

BSE - Scripe Code : 532660

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E),Mumbai – 400051

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on August 13, 2014, inter alia, have approved/resolved/taken note of the following:

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchange, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30,2014 attached herewith;
2. The Board took note of Auditor's Limited Review Report on the un Audited Financial Statements of the Company for the quarter ended June 30,2014
3. Appointment of Mr Vaidyanathan , as the Chief Financial Officer of the Company effective August 13 , 2014

**"Brief about Mr. Mr Vaidyanathan:**

Mr Vaidyanathan has more than two decades of experience in the area of Corporate Finance and has served as a CFO for more than a decade across his last two assignments.

Mr Vaidyanathan has multi-industry experience in the areas of Project Finance, Private Equity, IPO, Structured Finance, cross-border M&A, Taxation, Business Planning and Strategy. His last assignment was with the NSL group which has interests spanning from Agro-Seeds to Infrastructure, as the Group CFO handling all the M&A and fund-raising activities of the group along with review and monitoring of business plans of the Group companies.

Prior to this assignment, he was the CFO for Hostmann-Steinberg Inc, Illinois in North America, where he was instrumental in raising long term capital and was responsible for the business planning and budgeting of all group entities.



At prior points of his professional career he has also been associated with names across different industries like Bilag Industries (now part of Bayer AG), Stock Holding Corporation of India (SHCIL) & A. F Ferguson & Co.

Mr Vaidyanathan is a qualified Chartered Accountant from ICAI, India and an ICWA from the Institute of Cost Accountants of India. Additionally he has also passed, the Certified Public Accountant (CPA) and Certified Management Accountant (CMA) Examinations.

4. Directors Report for the financial year ended 31/03/2014 together with annexure thereto
5. Convening of Annual General Meeting (AGM) 30/09/2014 and Notice of AGM.
6. Fixed Book closure dates from September 26, 2014 to September 30, 2014 (both days inclusive) for the purpose of AGM & ascertaining eligibility to dividend .
7. Scheme of Amalgamation ("Scheme") of Klar Sehen Private Limited, Octtantis Nobel Labs Private Limited, Creative HealthCare Private Limited and Vivimed Labs (Alathur) Private Limited (collectively referred to as "Transferor Companies") being 100% subsidiaries, with Vivimed Labs Limited ("VLL").

The salient features of the Scheme are as under:

- a. Appointed Date shall be April 01, 2014;
- b. All assets and liabilities of the Transferor Companies would be transferred to VLL;
- c. Given the Transferor Companies are 100% subsidiaries of VLL, no shares would be issued as consideration for the merger. Investments held by VLL in subsidiaries would stand cancelled

The Scheme is subject to requisite approvals.

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD

**SANTOSH VARALWAR**  
**MANAGING DIRECTOR & CEO**





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

To  
The Board of Directors  
**M/s. Vivimed Labs Limited**  
Hyderabad

**Limited Review Report for the quarter ended 30<sup>th</sup> June 2014**

We have reviewed the accompanying statement of unaudited financial results of **M/s. Vivimed Labs Limited** for the quarter ended 30<sup>th</sup> June 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Company is in the process of computing the revised depreciation charge pursuant to the requirements of schedule II of the Companies Act, 2013. In the interim, during the current quarter, the management of the Company has calculated the depreciation accounted for in the financial statements for the quarter ended June 30, 2014 in line with schedule XIV of the Companies Act, 1956.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies, subject to our observations on depreciation as above, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



For P. Murali & Co.  
Chartered Accountants

  
A. Krishna Rao  
Partner  
M. No.020085

Place: Hyderabad  
Date : 13<sup>th</sup> August, 2014

**VIVIMED LABS LIMITED**  
**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30'2014**

Sl. No.	Particulars	₹ in Lacs			
		QUARTER ENDED			YEAR ENDED
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income From Operations</b>				
	(a) Net Sales / Income from Operations (Net of Excise Duty)				
	(b) Other Operating Income	96,653.65	36,817.32	34,075.44	135,083.30
	<b>Total Income From Operations (Net)</b>	122.48	390.42	316.03	821.51
	a. Cost of Raw Materials Consumed	36,776.13	37,207.74	34,391.47	135,904.81
	b. Purchase of Stock in Trade	18,761.49	19,033.52	15,039.05	66,370.82
	c. Changes in Inventories of finished inventories of Finished Goods, Work-in-Progress and Stock in Trade	(1,449.32)	(2,985.16)	2,717.58	(738.38)
	d. Employee Benefit Expenses	4,716.39	4,123.32	3,863.89	17,206.48
	e. Depreciation and Amortisation Expenses	1,650.15	1,714.96	1,465.42	6,611.62
	f. Other Expenditure	8,940.72	11,191.59	7,887.51	31,739.01
<b>2</b>	<b>Total Expenses</b>	32,619.43	33,078.23	30,973.45	121,189.55
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	4,156.70	4,129.51	3,418.02	14,715.26
<b>4</b>	<b>Other Income</b>				
<b>5</b>	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	4,156.70	4,129.51	3,418.02	14,715.26
<b>6</b>	<b>Finance Costs</b>	1,840.42	1,763.49	985.65	6,029.10
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	2,316.28	2,366.02	2,432.37	8,686.16
<b>8</b>	<b>Exceptional items</b>				
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	2,316.28	2,366.02	2,432.37	8,686.16
<b>10</b>	<b>Tax Expenses</b>	603.24	1,261.85	433.92	2,046.76
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	1,713.05	1,104.17	1,998.45	6,639.41
<b>12</b>	<b>Extraordinary items (net of tax expenses Rs.....Lacs)</b>				
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>	1,713.05	1,104.17	1,998.45	6,639.41
<b>14</b>	<b>Share of Profit / (Loss) of associates</b>				
<b>15</b>	<b>Minority Interest</b>				
<b>16</b>	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	1,713.05	1,104.17	1,998.45	6,639.41
<b>17</b>	<b>Paid up Equity Share Capital (Face value of the Share shall be indicated)</b>	1,620.38	1,620.38	1,606.09	1,620.38
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>				
<b>19</b>	<b>Earnings per Share (before Extraordinary Items) (of Rs10 /- each) (not annualised)</b>				
	(a) Basic	10.57	6.81	12.44	40.97
	(b) Diluted	10.57	6.81	12.44	40.97

1. The above Consolidated Unaudited Financial Results for the Quarter ended JUNE 30'14 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 13<sup>th</sup> August 2014

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Alothur) pvt Limited (vi) Finosa Pharma pvt Limited and its step down subsidiaries viz (vii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (viii) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico-Farmacéutica S.A.U., Spain, (iv) Holiday International Limited, UK & (v) Uquifa Mexico S.A. de C.V.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

6. The company is in the process of computing depreciation in accordance with the requirements of Schedule - II of the Companies Act 2013. In the interim, the company has calculated and provided for depreciation as per Schedule XIV of the Companies Act 1956. Adjustment, if any, on account of such change would be accounted for in the subsequent quarters on completion of such computation.

Place : Hyderabad  
 Date : 13-08-2014



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR & CEO

**VIVIMED LABS LIMITED**  
**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING**

₹ in Lacs

Particulars	QUARTER ENDED		YEAR ENDED	
	30-06-2014 (Unaudited)	31-03-2014 (Audited)	30-06-2013 (Unaudited)	31-03-2014 (Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	8,861.66	11,835.46	9,833.75	41,431.92
b.Pharma Business	27,791.99	24,981.86	24,241.69	93,651.38
<b>Total</b>	<b>36,653.65</b>	<b>36,817.32</b>	<b>34,075.44</b>	<b>135,083.30</b>
Less, Inter Segment Revenue				
<b>Net sales / Income from Operations</b>	<b>36,653.65</b>	<b>36,817.32</b>	<b>34,075.44</b>	<b>135,083.30</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>				
a.Speciality Chemicals Business	1,787.48	2,367.01	1,499.23	8,261.30
b.Pharma Business	2,369.22	1,762.50	1,918.79	6,453.96
<b>Total</b>	<b>4,156.70</b>	<b>4,129.51</b>	<b>3,418.02</b>	<b>14,715.26</b>
Less: 1.Interest	1,840.42	1,763.49	985.65	6,029.10
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
<b>Total Profit Before Tax</b>	<b>2,316.28</b>	<b>2,366.02</b>	<b>2,432.37</b>	<b>8,686.16</b>
<b>3. Capital Employed</b>				
a.Speciality Chemicals Business	81,593.43	80,029.16	79,125.29	80,029.16
b.Pharma Business	65,258.58	67,372.76	50,135.20	67,372.76
<b>Total</b>	<b>146,852.01</b>	<b>147,401.92</b>	<b>129,260.49</b>	<b>147,401.92</b>

Place : Hyderabad

Date :13-08-2014



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR & CEO

**VIVIMED LABS LIMITED**  
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30<sup>TH</sup> 2014

Sl. No.	Particulars	₹ in Lacs			
		Quarter Ended			YEAR ENDED
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income From Operations</b>				
	(a) Net Sales / Income from Operations (Net of Excise Duty)				
	(b) Other Operating Income	10,272.84	12,781.01	9,850.63	43,199.35
	<b>Total Income From Operations (Net)</b>	(1.90)	72.03	14.85	154.99
	a. Cost of Raw Materials Consumed	10,270.94	12,853.03	9,865.48	43,354.34
	b. Purchase of Stock in Trade	6,871.71	6,830.70	5,405.74	23,605.69
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade				
	d. Employee Benefit Expenses	(1,866.67)	(516.74)	403.39	(140.95)
	e. Depreciation and Amortisation Expenses	549.58	515.43	510.95	1,983.25
	f. Other Expenditure	448.16	454.71	406.17	1,806.35
<b>2</b>	<b>Total Expenses</b>	2,180.26	2,964.68	1,517.17	7,784.86
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	8,183.03	10,248.79	8,243.42	35,039.22
<b>4</b>	<b>Other Income</b>	2,087.91	2,604.24	1,622.06	8,315.12
<b>5</b>	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>				
<b>6</b>	<b>Finance Costs</b>	2,087.91	2,604.24	1,622.06	8,315.12
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	1,427.60	1,492.65	583.53	4,434.39
<b>8</b>	<b>Exceptional Items</b>	660.31	1,111.59	1,038.53	3,880.73
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>				
<b>10</b>	<b>Tax Expenses</b>	660.31	1,111.59	1,038.53	3,880.73
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	177.17	663.98	207.71	1,217.81
<b>12</b>	<b>Extraordinary Items (net of tax expenses Rs.....Lacs)</b>	483.14	447.61	830.82	2,662.92
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>				
<b>14</b>	<b>Share of Profit / (Loss) of associates</b>	483.14	447.61	830.82	2,662.92
<b>15</b>	<b>Minority Interest</b>				
<b>16</b>	<b>Net Profit / Loss after taxes, Minority interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	483.14	447.61	830.82	2,662.92
<b>17</b>	<b>Paid up Equity Share Capital (Face value of the Share shall be indicated)</b>	1,620.38	1,620.38	1,606.09	1,620.38
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>				
<b>19</b>	<b>Earnings per Share (before Extraordinary Items) (of Rs10/- each) (not annualised)</b>				
	(a) Basic	2.98	2.76	5.17	16.43
	(b) Diluted	2.98	2.76	5.17	16.43

1. The above Standalone Unaudited Financial Results for the Quarter ended JUNE 30<sup>TH</sup> 2014 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 13<sup>th</sup> August 2014

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website [www.vivimedlabs.com](http://www.vivimedlabs.com) and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

5. The company is in the process of computing depreciation in accordance with the requirements of revised Schedule - II of the Companies Act 2013. In the interim, the company has calculated and provided for depreciation as per Schedule XIV of the Companies Act 1956. Adjustment, if any, on account of such change would be accounted for in the subsequent quarters on completion of such computation.

Place : Hyderabad  
Date : 13-08-2014



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO

**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

₹ in Lacs

Particulars	QUARTER ENDED			YEAR ENDED
	30-06-2014	31-03-2014	30-06-2013	31-03-2014
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	7,999.69	10,440.43	7,575.10	35,112.23
b.Pharma Business	2,273.15	2,340.58	2,275.53	8,087.12
<b>Total</b>	<b>10,272.84</b>	<b>12,781.01</b>	<b>9,850.63</b>	<b>43,199.35</b>
Less, Inter Segment Revenue				
<b>Net sales / Income from Operations</b>	<b>10,272.84</b>	<b>12,781.01</b>	<b>9,850.63</b>	<b>43,199.35</b>
<b>2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>				
a.Speciality Chemicals Business	1,560.40	1,948.69	1,177.89	6,772.07
b.Pharma Business	527.51	655.55	444.17	1,543.05
<b>Total</b>	<b>2,087.91</b>	<b>2,604.24</b>	<b>1,622.06</b>	<b>8,315.12</b>
Less: 1.Interest	1,427.60	1,492.65	583.53	4,434.39
2.Other Un-allocable Expenditure				
3.Un-allocable Income				
<b>Total Profit Before Tax</b>	<b>660.31</b>	<b>1,111.59</b>	<b>1,038.53</b>	<b>3,880.73</b>
<b>3. Capital Employed</b>				
a.Speciality Chemicals Business	80,178.40	79,866.87	74,425.13	79,866.87
b.Pharma Business	27,036.96	29,180.79	14,727.13	29,180.79
<b>Total</b>	<b>107,215.36</b>	<b>109,047.66</b>	<b>89,152.26</b>	<b>109,047.66</b>

Place : Hyderabad  
Date :13.08.2014



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO

Part II					
Select Information for the Quarter and Year Ended 30/06/2014					
SL.No	Particulars	Quarter ended 30/06/2014	Quarter ended 31/03/2014	Quarter ended 30/06/2013	Previous Year ended 31/03/2014
A	<b>PARTICULARS OF SHAREHOLDING</b>				
	Public Shareholding				
	Number of Shares	10026058	10026058	9664136	10026058
	Percentage of Shareholding	61.87%	61.87%	60.17	61.87%
	Promoter and Promoter Group Shareholding				
	(a) Pledged/ Encumbered				
	Number of Shares	2750455	2482455	24,52,455	2482455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	44.52%	40.18%	38.34	40.18%
	Percentage of shares (as a % of the total share capital of the company)	16.98%	15.32%	15.27	15.32%
	(b) Non-encumbered				
	Number of Shares	3427270	3695270	39,44,335	3695270
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	55.48%	59.82%	61.66	59.82%
	Percentage of shares (as a % of the total share capital of the company)	21.15%	22.81%	24.56	22.81%

#### Investor's Complaints

Sl.no	Particulars	3 months ended 30/06/2014
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	Nil

*(Handwritten signature)*

